MedTrace Logo

A Phase IV Study to Assess the Impact of the Change of Antiretroviral Treatment From Dual Therapy to Triple Therapy on Inflammation in Patients With HIV Infection

NCT04076423 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 141

Last updated 2024-10-01

No results posted yet for this study

Summary

242 patients (121 patients in each of the two treatment arms) will be included with a confirmed diagnosis of HIV-1 infection and with a stable antiretroviral treatment during more than 48 weeks with dual therapy (DTG + 3TC)

Conditions

  • HIV Infections

Interventions

DRUG

Dual Therapy

DTG + 3TC

DRUG

Triple therapy

BIC / FTC / TAF

Sponsors & Collaborators

  • Fundacion SEIMC-GESIDA

    lead OTHER

Principal Investigators

  • Santiago Moreno, MD · Hospital Univ. Ramón y Cajal

  • Sergio Serrano, MD · Hospital Univ. Ramón y Cajal

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-10
Primary Completion
2023-06-15
Completion
2024-01-16

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04076423 on ClinicalTrials.gov